The findings from this study suggest that targeting the SIRT1-c-Myc axis using the small molecule inhibitors of SIRT1 could potentially improve outcomes of TKI-based treatment of FLT3-ITD AML. The gene discussed is FLT3; the disease is acute myeloid leukemia.